<DOC>
	<DOCNO>NCT00666185</DOCNO>
	<brief_summary>To determine efficacy safety IV Micafungin versus IV Fluconazole treatment patient Esophageal Candidiasis</brief_summary>
	<brief_title>Comparative Trial Micafungin Versus Fluconazole Treating Esophageal Candidiasis</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Oral</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Diagnosis esophageal candidiasis confirm endoscopy Negative pregnancy test female childbearing potential Pregnant nursing Evidence liver disease Presence another active opportunistic fungal infection and/or receive acute systemic therapy opportunistic fungal infection Concomitant esophagitis cause herpes simplex virus cytomegalovirus Receipt oral topical antifungal agent within 48 hour systemic agent within 72 hour first dose study drug Nonresponsive therapy prior systemic antifungal clinical trail History &gt; 2 episode esophageal candidiasis require systemic antifungal therapy History anaphylaxis attribute azole compound echinocandin class antifungal</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Micafungin</keyword>
	<keyword>Esophageal Candidiasis</keyword>
	<keyword>Fluconazole</keyword>
</DOC>